spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development


MedPharm’s Chief Scientific Officer and Co-Founder, Professor Marc Brown and University of Reading’s Professor Adrian Williams have co-authored the new book: ‘The Art and Science of Dermal Formulation Development”. It is the latest addition to ‘Drugs and the Pharmaceutical Sciences’, a series of textbooks and monographs published by CRC Press.

The Art and Science of Dermal Formulation development provides a comprehensive guide to all aspects of the subject, from the structure of skin and formulation development and performance testing to the chemical, physical and technological modulation of delivery and manufacturing processes.

Professor Brown said: “The book covers early stage preformulation and formulation development right through to product manufacture. Much of the information is based on the systems, processes and expertise we have built up at MedPharm over the years and which have successfully led to the commercial launch of over 50 products by our clients.

The global pharmaceutical dermatology market was valued at $52billion in 2018 and has been predicted to double over the next 10 years. Patients and consumers of over the counter (OTC) products globally are demanding higher standard of treatment from products which are easy to use, and which help compliance.

Prof. Brown continued: “The demand within the pharmaceutical industry for these specialised and complex development services continues to grow as more becomes known about the important biochemical process occurring in the skin. This shift within the industry has been reflected in the expanding demand for MedPharm’s services.”

Prior to co-founding MedPharm in 1999 and throughout his time at the company, Professor Brown has held full, part-time or visiting academic positions at several UK universities. Both Professors have co-authored over 300 research and technical publications and supervised over 100 graduate students in the field.

Dr Jon Lenn, MedPharm CTO added “The book provides an in-depth and coherent introduction to the discipline of topical and transdermal product development for the scientific community.

He continued “We are very pleased to be able to promote the science behind what we do. Innovating and ensuring we continue to develop our scientific expertise has been crucial and will remain fundamental to MedPharm’s future growth and support for its customers.”

For more information on MedPharm and its services, please visit: www.medpharm.com or for more information on the book, please visit https://www.crcpress.com/The-Art-and-Science-of-Dermal-Formulation-Development/Brown-Williams/p/book/9781138064928

ENDS

For further information, images and interview opportunities, please contact Celine Goodier at ramarketing: celine@ramarketingpr.com| +44 (0)191 222 1242 or www.ramarketingpr.com

NOTES TO EDITORS

About MedPharm
MedPharm Ltd. is a leading, global provider of contract topical and transdermal product design and formulation development services. MedPharm are experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through the use of proprietary, industry-leading performance testing models. Well-established as a global leader in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm also offers innovative solutions for ophthalmic and airway preparations. These solutions are recognised for their scientific rigor by regulators and investors. MedPharm has fully established R&D centres in the US and UK and GMP clinical manufacturing at its global headquarters facility in Guildford, UK. For more information visit our website www.medpharm.com.
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Gerresheimer opens a new plant for the production of pharmaceutical primary plastic packaging in China

Düsseldorf/Changzhou, December 11, 2019 – A new plant for producing plastic pharmaceutical packaging has been set up in the Chinese city of Changzhou to help satisfy the high demand for Gerresheimer’s primary packaging in China in the future. Today the new facility will be officially opened.
More info >>


White Papers

Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials

Perceptive Informatics

Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
More info >>

Industry Events

Evolution Summit

2-4 March 2020, The Meritage Resort & Spa, Napa, CA, USA

The 21st Evolution Summit is an invitation-only, premium Summit bringing leading clinical trial executives and innovative suppliers & solution providers together. The Summit’s content is aligned with key clinical trial challenges and interests, relevant market developments, and practical and progressive ideas and strategies adopted by successful pioneers.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement